News

Feb 01, 2012

Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
Read more here

Jan 18, 2012

Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Read more here

Jan 17, 2012

Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Read more here

Jan 13, 2012

Niiki Pharma Developing New Weapons to Battle Cancer
Read more here

Jan 05, 2012

Yaupon Changes Name to Ceptaris Therapeutics, Inc.
Read more here

Jan 03, 2012

Ossianix Announces Lundbeck Investment
Read more here

Dec 13, 2011

FDA Permits Marketing of the First Hand-held Device to Aid in the Detection of Bleeding in the Skull
Read more here

Dec 09, 2011

InfraScan Inc. Announces Issuance of US Patent for Hematoma Detection
Read more here

Dec 01, 2011

Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer
Read more here

Nov 15, 2011

Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
Read more here